Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  International Journal of Oncology

• Publication date

  2010-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/IJO_00000747PMID 20811718PMCID PMC6545580
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Histone Deacetylase Inhibitor Depsipeptide Activates Silenced Genes through Decreasing both CpG and H3K9 Methylation on the Promoter

  2008cited by this paper
• Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice

  2008cited by this paper
• Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes

  2008cited by this paper
• Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine

  2008cited by this paper
• Apoptosis Induced by Depsipeptide FK228 Coincides with Inhibition of Survival Signaling in Lung Cancer Cells

  2007cited by this paper
• Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?

  2007cited by this paper
• Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.

  2007cited by this paper
• The epigenomics of cancer.

  2007cited by this paper
• The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma.

  2006cited by this paper
• Epigenetic therapy of cancer: past, present and future

  2006cited by this paper
• Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura

  2006cited by this paper
• DNA methylation and gene silencing in cancer

  2005cited by this paper
• Zebularine: A Unique Molecule for an Epigenetically Based Strategy in Cancer Chemotherapy

  2005cited by this paper
• Sequential 5-Aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells

  2005cited by this paper
• Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

  2005cited by this paper
• Plasma Pharmacokinetics, Oral Bioavailability, and Interspecies Scaling of the DNA Methyltransferase Inhibitor, Zebularine

  2005cited by this paper
• Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase

  2004cited by this paper
• Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells

  2004cited by this paper
• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

  2004cited by this paper
• Preferential response of cancer cells to zebularine.

  2004cited by this paper
• Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme.

  2004cited by this paper
• Inhibition of DNA methylation and reactivation of silenced genes by zebularine.

  2003cited by this paper
• Synergistic antineoplastic action of DNA methylation inhibitor 5‐AZA‐2′‐deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells

  2003cited by this paper
• Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.

  2002cited by this paper
• Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

  2002cited by this paper
• Modulation of p 53 , ErbB 1 , ErbB 2 , and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR 901228

  2002cited by this paper
• Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer.

  2001cited by this paper
• Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells

  2001cited by this paper
• DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.

  2001cited by this paper
• Methylation Patterns of the E-cadherin 5′ CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression*

  2000cited by this paper
• Disruption of Myc-Tubulin Interaction by Hyperphosphorylation of c-Myc during Mitosis or by Constitutive Hyperphosphorylation of Mutant c-Myc in Burkitt's Lymphoma

  2000cited by this paper
• P21-dependent G 1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

  2000cited by this paper
• Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications.

  2000cited by this paper
• Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

  1999cited by this paper
• Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone.

  1999cited by this paper
• Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation.

  1999cited by this paper
• NEOPLASIA Loss of p 73 Gene Expression in Leukemias / Lymphomas Due to Hypermethylation

  1999cited by this paper
• Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.

  1998cited by this paper
• The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro

  1995cited by this paper
• CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine.

  1995cited by this paper
• Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB.

  1994cited by this paper
• Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

  1994cited by this paper
• Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.

  1994cited by this paper
• Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase.

  1986cited by this paper
• Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia.

  1985cited by this paper
• Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine.

  1984cited by this paper
• Analysis of combined drug effects: a new look at a very old problem

  1983cited by this paper
• Kinetics of phosphorylation of 5-aza-2'-deoxyycytidine by deoxycytidine kinase.

  1979cited by this paper
• A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems.

  1977cited by this paper

• Electrochemical Biosensor for Multiple Methylation-Locus Analysis Based on DNA-AuNPs and Bienzymatic Dual Signal Amplifications

  2020cites this paper
• Identifying Drug Sensitivity Subnetworks with NETPHIX

  2019cites this paper
• Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells.

  2018cites this paper
• CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition

  2018cites this paper
• Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic.

  2018cites this paper
• Targeting Histone Deacetylases in Diseases: Where Are We?

  2015cites this paper
• Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon

  2015cites this paper
• Epigenetic drugs for cancer therapy

  2015cites this paper
• The Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular Correlations

  2015cites this paper
• A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors

  2014cites this paper
• Prognostic significance of the expression levels of the p16, p15, and p14 genes in dogs with high-grade lymphoma.

  2014cites this paper
• Zebularine induces chemosensitization to methotrexate and efficiently decreases AhR gene methylation in childhood acute lymphoblastic leukemia cells

  2014cites this paper
• Breast Cancer Epigenetics: Biomarkers and Therapeutic Potential

  2013cites this paper
• DNA Methylation and Histone Deacetylation: Interplay and Combined Therapy in Cancer

  2012cites this paper
• Open Access Scientific Reports

  2012cites this paper
• Avaliação dos efeitos antineoplásicos da Zebularina em linhagens pediátricas de leucemia linfóide aguda

  2012cites this paper
• Achieving a cure for HIV infection: do we have reasons to be optimistic?

  2012cites this paper
• Tumor Suppressor Gene p16/INK4A/CDKN2A and Its Role in Cell Cycle Exit, Differentiation, and Determination of Cell Fate

  2012cites this paper
• DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer

  2011influential citation
• MicroRNA, epigenetic machinery and lung cancer

  2011cites this paper